Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Rhea-AI Summary
Lantern Pharma, Inc. (NASDAQ: LTRN) has launched 'Webinar Wednesdays' featuring top physician scientists and key opinion leaders discussing critical areas of oncology drug development. The webinars are set to be held monthly, starting on April 24th, 2024, with the first session focusing on non-small cell lung cancer and the LP-300 drug candidate. Subsequent sessions will cover pancreatic cancer and the LP-184 drug candidate, with renowned collaborators like Dr. Joseph Treat and Dr. Igor Astsaturov participating.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
-
Rhea-AI Summary
Lantern Pharma, a NASDAQ-listed AI company, gets approval to expand the Harmonic™ clinical trial for non-small cell lung cancer in never-smokers to Japan and Taiwan. Dr. Yashushi Goto will lead the trial, aiming to provide a therapeutic option for patients in East Asia, where lung cancer in never-smokers is prevalent. The unique mechanism of action of LP-300 targets distinct mutations in these patients, potentially revolutionizing treatment for this growing patient segment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.12%
Tags
-
News
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023. The company is actively engaged in multiple clinical trials for AI-guided drug candidates, with first data expected in the second half of 2024. Lantern Pharma has dosed initial patients in Phase 1 clinical trials for synthetic lethal drug-candidates LP-184 and LP-284, expanded Phase 2 LP-300 Harmonic™ clinical trial, and advanced Starlight Therapeutics towards a potential Phase 1B/2 clinical trial. The company exceeded its 2023 goal for oncology drug development AI platform RADR® and aims to achieve a 100 billion datapoint goal for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.8%
Tags
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announces dosing of first two patients in Phase 1 clinical trial for LP-284, a potential therapy for non-Hodgkin’s lymphoma and solid tumors. LP-284 is the second synthetic-lethal molecule from Lantern, with AI playing a crucial role. The drug has the potential to benefit 40,000 to 80,000 patients annually, with a global market potential of $4 billion USD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.37%
Tags
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) will host a webcast to discuss its fourth quarter and fiscal year 2023 financial results, along with upcoming milestones, clinical trials, and developments of its AI platform, RADR®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.58%
Tags
-
Rhea-AI Summary
Lantern Pharma (NASDAQ: LTRN) will present at a virtual conference hosted by HCW on March 7th. CEO Panna Sharma will discuss AI-driven cancer drug discovery. Investors can register for the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announces significant milestones in the growth and development of its RADR® AI platform for cancer drug discovery. The platform has exceeded 60 billion data points and is expected to reach 100 billion by 2024. Lantern focuses on enhancing data growth efforts in drug sensitivity, combination treatment outcomes, biomarker data in rare cancers, and synthetic lethal targets. The company aims to improve molecular optimization, feature extraction, and drug-drug interaction predictions. RADR®'s expansion enables more precise cancer therapy development, automating data collection, and curation processes efficiently.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) achieves a significant milestone in its ADC program by developing a novel cryptophycin-based ADC with potent anti-tumor activity. The company collaborates with academic partners to create highly specific and effective ADCs for various solid tumor indications. Leveraging RADR® AI platform and a unique conjugation approach, Lantern aims to advance towards IND development in 2024, targeting unresponsive solid tumors. The cryptophycin ADC shows superior potency and tumor-killing capabilities compared to existing ADCs, offering a promising solution for cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
-
Rhea-AI Summary
Starlight Therapeutics, a Lantern Pharma subsidiary, has announced the appointment of Marc Chamberlain, M.D. as its Chief Medical Officer. Dr. Chamberlain will oversee clinical operations and planned clinical trials for brain cancers. He brings extensive expertise in neuro-oncology and therapeutic development, which will be invaluable for advancing Starlight's AI-enabled and accelerated drug development portfolio. Starlight is focused on developing precision therapeutics for cancers with limited or no effective therapeutic options, such as pediatric and adult brain cancers. The company is preparing for recurrent glioblastoma studies and has developed a CNS penetrant wholly synthetic acylfulvene, LP-184, for targeting brain tumors. The announcement marks a significant step in the company's mission to transform oncology with AI-enabled drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) has received Orphan Drug Designation (ODD) for LP-284 from the U.S. FDA for the treatment of high-grade B-cell lymphoma with MYC and BCL2 rearrangements. The drug has shown potent anti-tumor activity in preclinical models and is being developed for several aggressive B-cell NHL, including MCL and HGBL. LP-284 received its second ODD this year, making a total of five orphan designations granted to Lantern. The ODD provides seven years of market exclusivity and eligibility for expedited drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
The current stock price of Lantern Pharma (LTRN) is $3.145 as of December 20, 2024.
What is the market cap of Lantern Pharma (LTRN)?
The market cap of Lantern Pharma (LTRN) is approximately 35.4M.
What does Lantern Pharma Inc. specialize in?
Lantern Pharma specializes in precision medicine for cancer treatment, using AI and ML to identify and treat patients who will benefit most from their therapies.
What is the RADR platform?
RADR is Lantern Pharma's proprietary AI and ML platform that uses oncology-focused data points and advanced algorithms to accelerate cancer drug development.
How does Lantern Pharma's approach reduce drug development costs?
By using biomarker-based genetic screening to target patients more likely to respond to their drugs, Lantern Pharma decreases the cost and time required for drug development.
What is the company's strategy for growth?
Lantern Pharma focuses on acquiring or partnering with promising drug and diagnostic companies to advance personalized medicine programs for cancer patients.
How does Lantern Pharma use AI in drug development?
The company uses its AI platform, RADR, to analyze oncology data and develop precision therapies more efficiently and accurately.
Who are the key collaborators with Lantern Pharma?
Lantern Pharma collaborates with world-class scientific advisors and partners to enhance its precision medicine initiatives.
What are some of Lantern Pharma's recent achievements?
Lantern Pharma has made significant advances in its precision therapies and expanded its pipeline, leveraging AI to address real-world cancer treatment challenges.
Why is precision medicine important in cancer treatment?
Precision medicine allows for more accurate targeting of treatments based on genetic markers, improving efficacy and reducing unnecessary side effects.
How does Lantern Pharma's strategy benefit cancer patients?
By focusing on precision medicine and AI, Lantern Pharma aims to deliver more effective treatments faster and at a lower cost, benefiting patients with more tailored therapies.
What is the significance of biomarker-based genetic screening?
Biomarker-based genetic screening helps identify patients who are most likely to benefit from specific treatments, improving the chances of successful outcomes.
Lantern Pharma Inc.
Nasdaq:LTRN
LTRN Rankings
LTRN Stock Data
35.42M
9.20M
14.75%
24.1%
1.64%
Biotechnology
Pharmaceutical Preparations
United States of America
DALLAS